-
公开(公告)号:US09889258B2
公开(公告)日:2018-02-13
申请号:US14361527
申请日:2012-11-30
申请人: Novo Nordisk A/S
发明人: Henrik Bengtsson , Jonas K. Pedersen , Rikke B. Andersen , Jeppe Sturis , Kezia A. Juul , Lars Eilertsen , Ulla Ribel-Madsen
CPC分类号: A61M5/24 , A61M5/2033 , A61M5/2466 , A61M5/3294 , A61M2005/1787 , A61M2005/2474
摘要: A drug delivery assembly includes a housing (110), a piston (120) axially displaceable in the housing, and a variable volume reservoir (105) formed by the housing and the piston and containing a fluid first drug. The assembly further includes an exterior fluid inlet (150) arranged in or configured to be arranged in fluid communication with the reservoir, a fluid outlet (145) arranged in or configured to be arranged in fluid communication with the reservoir, biasing means (130) configured for moving the piston forwards, and releasable retaining means (113) configured for retaining the piston in an initial position, whereby the biasing means is allowed to move the piston forwards to expel fluid drug from the reservoir when the retaining means is released.
-
公开(公告)号:US20150182595A1
公开(公告)日:2015-07-02
申请号:US14658358
申请日:2015-03-16
申请人: Novo Nordisk A/S
发明人: Helle Birk Olsen , Svend Havelund , Ulla Ribel-Madsen , Jeppe Sturis , Helle Naver , Morten Schlein , Svend Ludvigsen
IPC分类号: A61K38/28 , A61K47/18 , A61K31/455
CPC分类号: A61K38/28 , A61K9/0019 , A61K31/198 , A61K31/455 , A61K31/465 , A61K45/06 , A61K47/02 , A61K47/183 , A61K47/22 , A61K2300/00
摘要: Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.
摘要翻译: 包含胰岛素化合物或两种或更多种胰岛素化合物,烟碱化合物和氨基酸的混合物的胰岛素制剂。
-
公开(公告)号:US20140220029A1
公开(公告)日:2014-08-07
申请号:US14249819
申请日:2014-04-10
申请人: Novo Nordisk A/S
IPC分类号: A61K39/395 , A61K38/26
CPC分类号: A61K39/3955 , A61K38/26 , A61K39/39541 , A61K45/06 , A61K2300/00
摘要: Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound.
摘要翻译: 用于预防和干预1型糖尿病的方法和用途,包括施用CD3和GLP-1化合物的调节剂。
-
公开(公告)号:US20130281364A1
公开(公告)日:2013-10-24
申请号:US13671034
申请日:2012-11-07
申请人: Novo Nordisk A/S
发明人: Helle Birk Olsen , Svend Havelund , Ulla Ribel-Madsen , Jeppe Sturis , Helle Naver , Morten Schlein , Svend Ludvigsen
CPC分类号: A61K38/28 , A61K9/0019 , A61K31/198 , A61K31/455 , A61K31/465 , A61K45/06 , A61K47/02 , A61K47/183 , A61K47/22 , A61K2300/00
摘要: Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.
-
公开(公告)号:US20230192801A1
公开(公告)日:2023-06-22
申请号:US17961438
申请日:2022-10-06
申请人: Novo Nordisk A/S
发明人: Frantisek Hubalek , Mathias Norrman , Helle Birk Olsen , Peter Madsen , Thomas Boerglum Kjeldsen , Jeppe Sturis
摘要: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
-
公开(公告)号:US12122818B2
公开(公告)日:2024-10-22
申请号:US18541682
申请日:2023-12-15
申请人: Novo Nordisk A/S
发明人: Frantisek Hubalek , Mathias Norrman , Helle Birk Olsen , Peter Madsen , Thomas Boerglum Kjeldsen , Jeppe Sturis
摘要: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
-
公开(公告)号:US11498951B2
公开(公告)日:2022-11-15
申请号:US17117263
申请日:2020-12-10
申请人: Novo Nordisk A/S
发明人: Frantisek Hubalek , Mathias Norrman , Helle Birk Olsen , Peter Madsen , Thomas Boerglum Kjeldsen , Jeppe Sturis
摘要: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
-
公开(公告)号:US20220249619A1
公开(公告)日:2022-08-11
申请号:US17626025
申请日:2020-07-10
申请人: Novo Nordisk A/S
摘要: The invention concerns a soluble insulin preparation comprising NϵB29-hexadecandioyl-γ-Glu-(desB30) human insulin in a concentration from 1800 nmol/ml to 4200 nmol/ml, Zinc ions in a concentration from 4.0 Zn/6Ins to 7.0 Zn/6Ins, Niacinamide in a concentration from 110 mM to 220 mM or treprostinil in a concentration from 0.02 μg/ml to 1 μg/ml, Citrate in a concentration from 6 mM to 40 mM, and pH in the range from 7.0 to 8.0. The invention further comprises a method for using the soluble insulin preparation for reducing the blood glucose level in a mammal and a process for preparing the soluble insulin preparations.
-
公开(公告)号:US20240141011A1
公开(公告)日:2024-05-02
申请号:US18541682
申请日:2023-12-15
申请人: Novo Nordisk A/S
发明人: Frantisek Hubalek , Mathias Norrman , Helle Birk Olsen , Peter Madsen , Thomas Boerglum Kjeldsen , Jeppe Sturis
摘要: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
-
公开(公告)号:US20140336586A1
公开(公告)日:2014-11-13
申请号:US14361527
申请日:2012-11-30
申请人: Novo Nordisk A/S
发明人: Henrik Bengtsson , Jonas K. Pedersen , Rikke B. Andersen , Jeppe Sturis , Kezia A. Juul , Lars Eilertsen , Ulla Ribel-Madsen
IPC分类号: A61M5/24
CPC分类号: A61M5/24 , A61M5/2033 , A61M5/2466 , A61M5/3294 , A61M2005/1787 , A61M2005/2474
摘要: A drug delivery assembly comprises a housing (110), a piston (120) axially displaceable in the housing, and a variable volume reservoir (105) formed by the housing and the piston and containing a fluid first drug. The assembly further comprises an exterior fluid inlet (150) arranged in or configured to be arranged in fluid communication with the reservoir, a fluid outlet (145) arranged in or configured to be arranged in fluid communication with the reservoir, biasing means (130) configured for moving the piston forwards, and releasable retaining means (113) configured for retaining the piston in an initial position, whereby the biasing means is allowed to move the piston forwards to expel fluid drug from the reservoir when the retaining means is released.
摘要翻译: 药物递送组件包括壳体(110),在壳体中可轴向移动的活塞(120)和由壳体和活塞形成并容纳流体第一药物的可变容积储存器(105)。 该组件还包括布置在或配置为与储存器流体连通的外部流体入口(150),布置在或配置成与储存器流体连通的流体出口(145),偏置装置(130) 被配置为向前移动活塞,以及可释放的保持装置(113),其构造成用于将活塞保持在初始位置,由此当所述保持装置被释放时,所述偏压装置被允许向前移动所述活塞以从所述储存器排出流体药物。
-
-
-
-
-
-
-
-
-